Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Seragen Inc.

Division of Ligand Pharmaceuticals Inc.

Latest From Seragen Inc.

Gloucester Pharmaceuticals Inc.

Two subtypes of T-cell mediated lymphomas have been very difficult to treat using the existing cytotoxic chemotherapy treatments. CTCL and peripheral T-cell lymphoma (PTCL) patients receiving chemotherapy may experience severe, dose-limiting toxicities and develop resistance to the therapy. Gloucester Pharmaceuticals Inc. is developing a treatment that potentially is more effective than chemo, the company says, and the National Institutes of Health is backing its development.

Monetizing Future Prospects Now

Investors in the drug business have had to choose between high-risk, high-reward biotechnology and lower-risk, established pharmaceutical companies with predictable earnings streams. In either case, they take on development risk--the possibility that products will fail in clinical trials and affect the company working on them. But now Paul Capital Partners hopes to capitalize on the largely unexplored niche of investing only in commercial risk. It recently closed its $300 million Royalty Acquisition Fund to effectively buy out streams of royalties from marketed products, paying up-front for a drug's lifetime of royalties.
BioPharmaceutical Business Strategies

Have Problem? Try M&A.

M&A was the universal prescription for the medical industry in 1998 as acquisition dollar volumes hit record levels. For some, the dealmaking further separates the haves and have-nots. For others, it's an addictive drug for coping with chronic insufficiency syndrome. But for nearly everyone who's using it, M&A is the easiest, if not always an effective, answer to the increasingly intractable problem of growth.
BioPharmaceutical Medical Device

Earnouts and Biotechnology Acquisitions

Acquisitions of biotechnology companies have been rare, in part, because of the challenge of valuing them. Target companies are usually years away from earnings; the stock prices of both the acquirer and target often fluctuate widely; and acquirers are afraid that a biotech's most valuable assets--its people--will walk away after the deal. earnouts can be helpful in addressing all of these issues.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Ligand Pharmaceuticals Inc.
  • Senior Management
  • Paul V Maier, CEO
  • Contact Info
  • Seragen Inc.
    Phone: (508) 497-0700
    97 South St.
    Hopkinton, MA 01748-